2nd Mitochondria-Targeted Drug Development Summit
We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, return for its 2nd edition.
Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.
From basic research to the clinic, this year’s meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine.
Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies.